Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3284 |
Name | thymic carcinoma |
Definition | A thymus cancer that derives_from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer immune system cancer thymus cancer thymic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
KIT D579del | Imatinib | thymic carcinoma | sensitive | detail... |
KIT Y553N | Imatinib | thymic carcinoma | sensitive | detail... |
KIT V560del KIT over exp | Imatinib | thymic carcinoma | predicted - sensitive | detail... |
KIT P577_D579del | Sorafenib | thymic carcinoma | predicted - sensitive | detail... |
KIT D820E | Sorafenib | thymic carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01011439 | Phase II | Milciclib | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | Terminated | USA | ITA | FRA | 0 |
NCT01025089 | Phase II | Cetuximab Cisplatin + Cyclophosphamide + Doxorubicin | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | Active, not recruiting | USA | 0 |
NCT01301391 | Phase II | Milciclib | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | Terminated | USA | ITA | 0 |
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01621568 | Phase II | Sunitinib | Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | Completed | USA | 0 |
NCT02364076 | Phase II | Epacadostat + Pembrolizumab | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | Unknown status | USA | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT03076554 | Phase II | Avelumab | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | Recruiting | USA | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
NCT03134118 | Phase II | Nivolumab | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM) | Active, not recruiting | NLD | GBR | FRA | ESP | CHE | BEL | 0 |
NCT03193437 | Phase II | Selinexor | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | Terminated | USA | 0 |
NCT03295227 | Phase I | Pembrolizumab | Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma | Recruiting | USA | 0 |
NCT03449173 | Phase II | Sunitinib | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) (Style) | Unknown status | ITA | 0 |
NCT03463460 | Phase II | Pembrolizumab + Sunitinib | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | Recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03583086 | Phase Ib/II | Nivolumab + Vorolanib | H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | Completed | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03694002 | Phase II | Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Ramucirumab | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT04417660 | Phase II | Bintrafusp alfa | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | Recruiting | USA | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04710628 | Phase II | Lenvatinib + Pembrolizumab | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI) | Active, not recruiting | ITA | FRA | ESP | 0 |
NCT04925947 | Phase II | KN046 | Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | Terminated | USA | 0 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT06248515 | Phase II | Sacituzumab govitecan-hziy | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Recruiting | USA | 0 |